



Volume 2, Issue 10
November 2023

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives **E_z - MINUTES**

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- Buprenorphine Extended-Release Injection (BRIXADI)

Drugs Added to the VA National Formulary WITH Prior Authorization

- Sulbactam + Durlobactam (XACDURO)
- Meropenem + Vaborbactam (VABOMERE)
- Imipenem + relebactam + cilastatin (RECARBRIO)
- Enfortumab vedotin (PADCEV)
- Aripiprazole ABILIFY ASIMTUFI
- Eribulin (HALAVEN)
- Ixabepilone (IXEMPRA)
- Neratinib (NERLYNX)
- Lapatinib (TYKERB)
- Paclitaxel protein-bound (ABRAXANE)
- Irinotecan HCL liposome (ONIVYDE)
- Alectinib (ALECENSA)
- Entrectinib (ROZYL TREK)
- Selpercatinib (RETEVMO)

Drugs Not Added to the VA National Formulary

- Nirsevimab-ALIP
- Metronidazole suspension (LIKMEZ)
- Anthrax vaccine, adsorbed, adjuvanted (CYFENDUS)
- Avapritinib (AYVAKIT)
- Futibatinib (LYTGOBI)
- Risperidone UZEDY:
- Treprostinil Oral Inhalation (TYVASO DPI)
- Colchicine (LODOC) 0.5 mg tablet: Added to the No Buy list - Colchicine 0.6 mg tablet is on the VANF

Formulary Drugs with Prior Authorization Removed

- Buprenorphine Extended-Release Injection (SUBLOCADE) for treatment of moderate-to-severe opioid use disorder.

Drugs Removed from the VA National Formulary

- Insulin detemir (LEVEMIR)

Other Announcements

- Fecal microbiota, live (REBYOTA) criteria for use revised
- Ceftolozane + tazobactam, ceftazidime + avibactam and Cefiderocol PA-F revised
- The Antipsychotic Long-acting injection Criteria for Use document replaced with individual antipsychotic LAI CFUs
 - Aripiprazole ABILIFY ASIMTUFII Criteria
 - Aripiprazole ARISTADA and ARISTADA INITIO Criteria revised
 - Aripiprazole MAINTENA Criteria revised
 - Fluphenazine decanoate Criteria revised
 - Haloperidol decanoate Criteria revised
 - Paliperidone INVEGA HAFYERA Criteria revised
 - Paliperidone INVEGA SUSTENNA Criteria revised
 - Paliperidone INVEGA TRINZA Criteria revised
 - Risperidone RISPERDAL CONSTA Criteria revised
- The Inhaled Prostacyclin Criteria for Use document replaced with individual Criteria for treprostinil inhalation by indication
 - Treprostinil Inhalation TYVASO Criteria for Pulmonary Hypertension Associated with Interstitial Lung Disease
 - Treprostinil Inhalation TYVASO Criteria Pulmonary Arterial Hypertension revised
- Prasugrel (EFFIENT) and Ticagrelor (BRILINTA) Criteria revised